Tumor-repopulating cells (TRCs) are a tumorigenic sub-population of cancer cells that drives tumorigenesis. We have recently reported that soft fibrin matrices maintain TRC growth by promoting histone 3 lysine 9 (H3K9) demethylation and Sox2 expression and that Cdc42 expression influences H3K9 methylation. However, the underlying mechanisms of how soft matrices induce H3K9 demethylation remain elusive. Here we find that TRCs exhibit lower focal adhesion kinase (FAK) and H3K9 methylation levels in soft fibrin matrices than control melanoma cells on 2D rigid substrates. Silencing FAK in control melanoma cells decreases H3K9 methylation, whereas overexpressing FAK in tumor-repopulating cells enhances H3K9 methylation. Overexpressing Cdc42 or RhoA in the presence of FAK knockdown restores H3K9 methylation levels. Importantly, silencing FAK, Cdc42, or RhoA promotes Sox2 expression and proliferation of control melanoma cells in stiff fibrin matrices, whereas overexpressing each gene suppresses Sox2 expression and reduces growth of TRCs in soft but not in stiff fibrin matrices. Our findings suggest that low FAK mediated by soft fibrin matrices downregulates H3K9 methylation through reduction of Cdc42 and RhoA and promotes TRC growth.
Introduction
Cancer stem cells (CSCs) are a subpopulation of cancer cells within a tumor that possesses self-renewing capability and drives tumor progression and metastasis. It has been demonstrated that TICs (tumor-initiating cells) or CSC-like cells exist in several types of cancer, including blood [1] , brain [2, 3] , skin [4, 5] , colon [6] , and intestine [7] . These tumorigenic cells are resistant to conventional chemotherapy and radiotherapy and speculated to be key players in cancer relapse [8, 9] . Therefore, understanding the molecular mechanisms underlying TIC's high tumorigenicity is essential to achieve complete tumor eradication. We previously mechanically selected tumorigenic B16 tumor-repopulating cells (TRCs) by culturing single cancer cells from cancer cell lines or primary tumors in three-dimensional (3D) soft fibrin matrices [4] . The selected TRCs exhibit high tumorigenic potential as they can efficiently repopulate tumors locally and in distant organs in wild-type syngeneic and non-syngeneic mice. These CSC-like TRCs express the same levels of surface stem cell marker CD133 as the unselected B16 cells. Therefore, these cells are different from CSCs. These TRCs are also different from tumor-initiating cells (TICs) that have 3 distinct subtypes of transient, delayed contributing, and long-term self-renewing. Soft fibrin matrices regulate TRC growth by promoting histone 3 lysine residue 9 (H3K9) demethylation that is associated with Cdc42 downregulation and Sox2 expression [10] . However, the underlying mechanisms of how soft fibrin matrices regulate H3K9 demethylation remain elusive. Here we demonstrate that focal adhesion kinase (FAK) regulates H3K9 methylation via Cdc42 and RhoA. Soft fibrin matrices maintain TRC growth by downregulating FAK, which in turn lowers Cdc42 and RhoA to mediate H3K9 demethylation and Sox2 upregulation.
Materials and methods

Cell culture
Murine melanoma cell line B16-F1 was purchased from American Type Culture Collection. Human breast cancer cell line MCF-7 and human lung cancer cell line A549 were obtained from Chinese Type Culture Collection. Briefly, cells were cultured on rigid dishes in cell culture medium supplemented with 10% fetal bovine serum (Invitrogen), 2 mM L-glutamine (Invitrogen), 1 mM sodium pyruvate and 0.1 mM penicillin/streptomycin at 37 C with 5% CO2.
Polyacrylamide and 3D fibrin gel preparation
Polyacrylamide gels were prepared following the protocol reported previously [11] . 3D fibrin gels were prepared as described previously [4, 10] . Briefly, fibrinogen was diluted with T7 buffer. Fibrinogen and single cell solution mixture was made by mixing the same volume. 250 ml cell/fibrinogen mixture was seeded into each well of 24-well plate and mixed well with pre-added 5 ml thrombin (100 U/ml). The cell culture plate was then incubated in 37 C cell culture incubator for 10 min. Finally, 1 ml of cell medium was added.
qPCR analysis
Total mRNA was isolated from cells using the RNeasy Mini Kit (QIAGEN) according to the supplier's instruction. qPCR was performed using the SsoAdvanced™ Universal Probes Supermix (BioRad). The data were normalized against mouse GAPDH. The sequences of all the primers were listed in the Supplemental Table 1 .
Western blotting assay
To quantify the expressions of FAK, H3K9 di-and trimethylation, cells were lysed with RIPA lysis buffer (Beyotime).
20 ml of each sample was separated by 8e15% SDS-PAGE, blocked with 5% BSA overnight at 4 C and incubated with primary antibodies to FAK (Rabbit, 1:1000, Abcam, ab40794), FAK-Y397 (Rabbit, 1:1000, Abcam, ab81298), H3K9 di-methylation (Rabbit, 1:300, Millipore, 17e648) and tri-methylation (Rabbit, 1:300, Millipore, 17e625), Histone H3 (Rabbit, 1:500, CST, #D1H2),, RhoA (Rabbit, 1:500, Abcam, ab187027), and GAPDH (Mouse 
Chromatin immunoprecipitation assay
We performed ChIP assay following the manufacturer's instructions (EZ-ChIP kit, Millipore). Briefly, cells were subjected to cross-linking with 1% formaldehyde in medium for 10 min at 37 C and then lysed on ice. Chromatin was sonicated to shear DNA to an average length of 0.2e1.0 kb. Antibodies to di-and tri-methylhistone H3 (Lys9) (Abcam) were used for immunoprecipitation. Normal mouse IgG (Santa Cruz) was used as negative control. The immunoprecipitation was heated to reverse the formaldehyde cross-linking and the DNA fragments in the precipitates was purified for qPCR analysis.
FRET imaging
The Lyn-FAK and H3K9 biosensors used in this study were reported elsewhere. The specificity of Lyn-FAK [10, 12] and H3K9 FRET biosensors [13] were determined using appropriate controls and point-mutations. The biosensors were transfected into cells. A Leica inverted fluorescence microscope integrated with Dual-View MicroImager system (Optical Insights) was used to capture CFP and YFP (YPet) emission images. For FRET imaging, each CFP and YFP image were simultaneously captured on the same screen by using a charge-coupled device camera (C4742-95-12ERG; Hamamatsu). A customized Matlab (Mathworks) program was used to analyze YPet/CFP (for H3K9 methylation) or CFP/YFP (for FAK activity) emission ratios.
RNA interference
Cells were transfected with siRNAs and complementary DNA using Lipofectamine 2000 (Invitrogen) following the manufacturer's protocol. The construct sequences were shown in Supplemental Table 2 . Knocking down or overexpression efficiency of the protein levels was shown in Supplemental Fig. 1 .
Statistical analysis
Two-tailed Student's t-test was used to conduct all the statistics.
Results
Soft matrices promote TRC growth via low FAK
We have reported that soft fibrin matrices decrease H3K9 methylation, increase Sox2 (a self-renewal gene) expression, and promote TRC's high tumorigenicity [4, 10] . However, the early cascade of matrix-cell mechanical signaling remains elusive. It is known that cells sense and respond to extracellular matrices mainly through integrin-mediated adhesion [14e16] . As one of the first proteins that interacts with cytoplasmic tails of integrins, FAK is abnormally expressed in several types of cancer and involved in tumor progression and metastasis [17e19]. We hypothesized that FAK might play a critical role in regulating TRC growth. To demonstrate the functional roles of FAK and the downstream molecules Cdc42 and RhoA in TRC growth, we examined their effects on the colony growth in 3D fibrin matrices. Melanoma cells expressed higher FAK, Cdc42, RhoA, and methyltransferases and lower Sox2 in stiff (1050-Pa) than in soft (90-Pa) 3D fibrin gels (Supplemental Fig. 2A and B) . Overexpressing FAK or Cdc42 or transfecting a constitutively active construct RhoA V14 in TRCs suppressed the colony growth in soft (Fig. 1A) but not in stiff fibrin matrices (Supplemental Fig. 3A ). This finding is supported by the results that overexpressing these genes inhibited TRC growth via suppression of Sox2 gene expression in soft (Fig. 1B) but not in stiff fibrin gels (Supplemental Fig. 3B ), possibly because Sox2 is already very low in stiff fibrin gels [10] . On the other hand, silencing FAK, Cdc42, or RhoA in control melanoma cells increased colony growth in stiff fibrin matrices (Fig. 1C) , possibly due to upregulation of Sox2 expression (Fig. 1D) . Interestingly, silencing FAK or Cdc42 but not RhoA promoted colony growth in soft fibrin matrices (Supplemental Fig. 3C ) without upregulating Sox2 gene expression (Supplemental Fig. 3D ), likely because Sox2 expression was already very high in the soft matrices and thus could not be elevated further. These findings suggest that FAK and its downstream molecules Cdc42 and RhoA may negatively regulate the growth of TRCs and that local matrix stiffness influences tumor growth by modulating Sox2 expression through these genes.
Next we examined whether matrix rigidity might influence FAK in melanoma cells. In comparison to control melanoma cells, TRCs expressed lower FAK mRNA ( Fig. 2A, top panel) , lower level of FAK protein and substantially lower Y-397 phosphorylation of FAK ( Fig. 2A, bottom panel) , suggested that both of total FAK protein amount and FAK activity decreased in TRCs. Because TRCs could maintain their mechanical memory on rigid glass for 5 days [10] , we re-plated TRCs back onto 2D rigid glass for 7 days and found that FAK mRNAs and activity were significantly increased toward the level of control B16 cells (Fig. 2A) . We further assayed colony growth in stiff fibrin matrices after inhibiting FAK activity pharmacologically with PF573228, and found that inhibiting FAK activity without changing FAK amounts also significantly increased colony growth in stiff fibrin matrices (Supplemental Fig. 4 ), suggesting that both of the FAK protein amount and activity contribute to TRC growth. To further explore if FAK downregulation in TRCs was due to lack of b1 integrin attachment, we cultured B16 cells on 90-Pa collagen-1 gel surfaces and compared FAK activity with control cells on collagen-1 coated rigid plastic. FAK mRNAs, protein levels, and activity all significantly decreased when compared with control cells (Fig. 2B) , suggesting that low FAK levels and low FAK activity are a result of the low substrate stiffness and not due to difference in integrin subtypes. The findings of low FAK amount and activity in B16 melanoma cells in 90-Pa fibrin gels were confirmed in human breast cancer MCF-7 cells and human lung cancer A549 cells cultured in 90 Pa fibrin gels (Supplemental Fig. 2C and D), suggesting that low FAK in growing TRCs in soft matrices is not limited to murine melanoma cells.
Association of low FAK activity with low H3K9 methylation
Next, we examined how FAK influenced Sox2 expression. B16 TRCs exhibited lower gene expressions of H3K9 methyltransferases EHMT2 and SUV39h1 and lower H3K9 di-and tri-methylation [10] . To quantify FAK activity and H3K9 methylation at the single cell level, we used a FAK biosensor [12] and a H3K9 methylation biosensor [10, 13] , both of which are based on the principle of fluorescence resonance energy transfer (FRET). To better understand the underlying mechanisms, we set out to determine the dynamic changes of FAK activity and H3K9 methylation of melanoma cells at early time points (up to 48 h) after being cultured in soft fibrin gels. To rule out the effect of apoptosis, only cells with no detectable morphological signs of apoptosis (e.g., no shrinkage of cell volume and no blebbing) were chosen for experiments. Indeed, after FRET measurements, these same cells were able to continue to proliferate in the next few days. Our data show that both FAK activity and H3K9 methylation started to decrease as early as 3 h and stayed at the reduced levels up to 48 h after culture in soft (90-Pa) fibrin gels (Fig. 2C, E) , which was further confirmed by western blotting assayed after 12 and 24 h in the soft gels (Fig. 2D, F) . We recently has shown that B16 TRCs lose Sox2 expression on rigid substrates [10] . Here we found that FAK mRNA expression and activity (Supplemental Figs. 5A and 6A), EHMT2 and SUV39h1 mRNA expression (Supplemental Fig. 5B ), and H3K9 methylation levels (Supplemental Fig. 6B ) increased with culture time when TRCs were plated back (up to 7 days) onto the rigid glass. These results demonstrate that FAK activation levels and H3K9 methylation levels are closely associated in melanoma cells. . In (A), significant differences between TRC and TRC þ FAK cDNA, TRC þ Cdc42 cDNA, or TRC þ RhoA V14 from day 3 to day 5. In (C), significant differences between Neg Ctr (negative control) and FAK siRNA #1, Cdc42 siRNA #1, or RhoA siRNA from day 2 to day 5. After 5 days, the mRNAs were extracted for analysis of Sox2 expression by qPCR in (B) and (D) (n ¼ 3 independent experiments). * P < 0.05 in all subfigures.
FAK regulates H3K9 methylation through small GTPases
Since FAK is a cytoplasmic protein tyrosine kinase that serves as a critical mechanosensor in integrin-mediated mechanotransduction [15, 16, 20, 21] , we wondered whether soft fibrin matrices induce H3K9 demethylation in the nucleus through FAK. Silencing FAK significantly decreased H3K9 methylation in control melanoma cells on the rigid glass ( Fig. 3A and B; Supplemental  Fig. 8A ). Melanoma cells elevated their H3K9 methylation on 2D stiff substrates (8-kPa) or in 3D stiff fibrin gels (1050-Pa) compared to cells on soft substrates (0.15-kPa) or to cells in 3D soft (90-Pa) fibrin gels, which was abolished after FAK inhibition (Supplemental Fig. 7A and 7B, Supplemental Fig. 8B ). Overexpressing FAK in melanoma cells increased H3K9 methylation in 3D soft fibrin gels but not on the rigid glass (Supplemental Fig. 7C and 7D) . These results suggest that FAK regulates H3K9 methylation.
As the downstream proteins of FAK and key cytoskeleton regulators [19,22e24] , Cdc42 and RhoA gene expression levels were downregulated in TRCs compared to control melanoma cells and both were increased after plating TRCs back to the rigid glass (Supplemental Fig. 5C and D) . We have shown previously that silencing Cdc42 significantly decreased H3K9 methylation of control melanoma cells [10] , which is supported by the data at the single-cell level on the rigid glass (Fig. 3C and D and Supplemental  Fig. 8C ). On the other hand, knocking down RhoA or inhibiting Rho kinase (ROCK) with 10 mM Y-27632 in control melanoma cells significantly decreased H3K9 methylation (Fig. 3E and F and Supplemental Fig. 8D . These data suggest that both Cdc42 and RhoA regulate H3K9 methylation. To determine if FAK regulates H3K9 methylation through Cdc42 and RhoA, we knocked down FAK but overexpressed Cdc42 or RhoA or transfected RhoA V14 in control melanoma cells and then cultured them on 2D substrates. Overexpressing Cdc42 or RhoA or transfecting RhoA-V14 restored H3K9 methylation levels even when FAK was silenced (Supplemental Fig. 7E and 7F) . Interestingly, when RhoA was silenced, overexpressing Cdc42 restored H3K9 methylation levels (Supplemental Fig. 9A and 9B) , suggesting that there might be an interplay between Cdc42 and RhoA in regulating H3K9 methylation.
Low FAK mediates H3K9 demethylation and Sox2 upregulation
We have recently reported that H3K9 demethylation increases Sox2 expression and growth of TRCs [10] . We further asked whether and how low levels of FAK promoted Sox2 expression in TRCs. In control melanoma cells, knocking down FAK inhibited the gene expressions of Cdc42, RhoA, EHMT2, and SUV39h1 and increased Sox2 gene expression (Fig. 4A) ; silencing Cdc42 decreased the gene expressions of FAK, RhoA, EHMT2, and SUV39h1 and increased Sox2 gene expression (Fig. 4B) ; inhibiting RhoA had no effect on FAK expression but significantly inhibited the gene expressions of Cdc42, EHMT2, and SUV39h1 and increased Sox2 expression (Fig. 4C) . Our previous chromatin immunoprecipitation (ChIP) data showed that EHMT2 and SUV39h1 methylated H3K9 at the Sox2 promoter site block Sox2 expression and that silencing EHMT2 or SUV39h1 significantly increased Sox2 expression. Importantly, EHMT2 and SUV39h1 are important in regulating tumor cell growth in soft fibrin gels [10] . To further explore if FAKCdc42/RhoA-H3K9 methylation pathway regulate Sox2 directly by binding to its promoter region, we performed ChIP assay to test the H3K9 methylation levels on Sox2 promoter region after silencing FAK. We found that H3K9 methylation levels on Sox2 promoter region were significantly downregulated after silencing FAK (Fig. 4D) . These findings suggest that low FAK induces H3K9 demethylation at the Sox2 promoter region and thus Sox2 upregulation via downregulation of Cdc42 and RhoA.
Discussion
In the current study, we have found that compared to control melanoma cells on the rigid glass, CSC-like TRCs exhibit low amount and low Y397 phosphorylation of FAK and high Sox2 expression. Recently we have demonstrated that TRCs are undifferentiated cells since they express low levels of Mitf and high levels of Sox2 [10, 25] . Importantly, we find that silencing FAK in control melanoma cells increases Sox2 expression in stiff but not in soft fibrin matrices and promotes growth in both soft and stiff fibrin matrices, whereas overexpressing FAK in TRCs decreases Sox2 expression and suppresses growth in soft but not in stiff fibrin matrices.
It has been reported that FAK is overexpressed in several types of cancer and responsible for high tumorigenicity and metastatic potential of tumor cells [26e28] . These findings have led to the development of FAK inhibitors as a potential anticancer therapy. The discrepancy between previous reports and our current study may result from the fact that most of the total population of tumor cells are probably differentiated tumor cells in those previous reports whereas only undifferentiated TRCs are analyzed in our present study [10] . Our results are consistent with the previous findings that the reduction in FAK activity promotes growth of stem cells [29] while the elevation in FAK activity facilitates their differentiation [30] . These findings may explain why FAK inhibition may not block tumorigenic cell proliferation as the current strategy in clinical trials of the candidate drugs to inhibit FAK does not work [31] . Nevertheless, we acknowledge that our current findings are limited only to a few types of tumor cells and whether they can be extended to other types of cancer or to in vivo condition should be interrogated rigorously.
Based on our current findings, we propose a working model for the signaling pathways of soft-fibrin induced TRC's growth (Supplemental Fig. 10 ). Cells sense mechanical forces from soft fibrin matrices via integrin subset avb3, which is the receptor of fibrin/fibrinogen [4] . FAK, one of the first molecules downstream of integrin, serves as a mechanosensor and mediates force transduction into the cells. Soft fibrin matrices downregulate FAK that lowers Cdc42 and RhoA. The reduced levels of Cdc42 and RhoA reorganize the cytoskeletal structure, disassemble the stress fibers, and decrease the cytoskeletal tension [32] . However, it is still not clear how Cdc42 and RhoA regulate H3K9 methylation in the nucleus. One possibility is that LINC (Liner of Nucleoskeleton of Cytoskeleton complex) couples the propagation of low forces into the nucleus [33] . Low forces further induce H3K9 demethylation at the region of Sox2 promoter [10] , which promotes Sox2 expression and TRC growth. In addition, it is well-documented that histone modification including H3K9 methylation regulates nuclear architecture and chromatin assembly and condensation [34] . Nevertheless, the exact signaling pathways of matrix-softnessdependent tumorigenicity remain to be elucidated in the future.
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